Eli Lilly and Company
Funding rounds backed by Eli Lilly and Company.
- Funding disclosed in full
- $735.5M
- Median round
- $48.5M
- Rounds in calculation
- 10
| Company | Round | Market | Investors | Announced | Details |
|---|---|---|---|---|---|
| Leal Therapeutics Develops neuro-metabolic therapeutics for schizophrenia and ALS | $30MSeries A | BiotechUnited States | |||
| Amplifica Holdings Group Clinical-stage biopharma developing injectable therapies for hair loss | $26MSeries B | BiotechUnited States | |||
| InduPro Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease | $77MSeries B | BiotechUnited States | |||
| Remedium Bio Develops durable protein therapeutics via gene therapy for chronic diseases | $10MSeries A | BiotechUnited States | |||
| Ratio Therapeutics Developing best-in-class radiopharmaceuticals for cancer treatment | $70MSeries C | BiotechUnited States | |||
| AdvanCell Develops lead-212 targeted alpha therapies to treat cancer | $315MSeries D | BiotechAustralia | 19 participantsAbingworthAlly Bridge GroupAlpha WaveBain Capital Life SciencesBrandon CapitalCatalio Capital ManagementEli Lilly and CompanyEventide Asset ManagementFidelity Management & Research CompanyMorningsidePiper HeartlandProto AxiomSanofi VenturesSV Health InvestorsSymBiosisTenmileTime BioVenturesT. Rowe Price AssociatesVelosity Capital | ||
| TRIMTECH Therapeutics Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases | $47MSeed+ | BiotechUnited Kingdom | |||
| Crossbow Therapeutics Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers | $77MSeries B | BiotechUnited States | |||
| TRex Bio Develops precision immunoregulatory medicines based on tissue Treg biology | $50MUndisclosed | BiotechUnited States | |||
| Juvena Therapeutics Develops regenerative biologics to restore tissue function | $33.5MSeries B | BiotechUnited States |